Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

BioTime (AMEX: BTX) receives NIH Approval for 4 GMP hES Cell Lines

Approved for use in federally funded research

BTX’s 4 human embryonic stem (hES) cell lines: ESI-035, ESI-049, ESI-051 and ESI-053, developed by a BioTime subsidiary have been approved by the NIH for inclusion in the NIH Human Embryonic Stem Cell Registry.

The Bottom Line: This approval opens the door to the use of these cell lines in federally funded research. The NIH created the Human Embryonic Stem Cell Registry in 2001 to facilitate research using human embryonic stem cells. The registry includes hES cell lines that meet certain eligibility criteria including ethical derivation and informed consent. Only research projects using hES cell lines listed in the Registry are eligible for federal funding.